MedPath

Tranexamic Acid : Nebulization vs IV Route for Hemoptysis

Not Applicable
Recruiting
Conditions
Hemoptysis
NEBULIZATION
Tranexamic Acid
Interventions
Drug: Tranexamic Acid (TXA)
Registration Number
NCT07212452
Lead Sponsor
University of Health Sciences Lahore
Brief Summary

This study compares the effect of tranexamic acid on hemoptysis when guven through the conventional IV route and Through nebulization.

Detailed Description

We are conducting a randomized controlled trial for the comparison of routes through which tranexamic acid can be given to control hemoptysis. The study participants will be divided into 2 groups randomly and 1 group will be assigned to use IV route while other will be assigned the nebulization route and the result variables include the time taken for complete control of hemoptysis and recurrence time. Another variable is also the reduction in amout of blood in sputum after each intervention.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
172
Inclusion Criteria
  1. Patients with mild to moderate hemoptysis < 600ml/ 24 hours of age 12 to 80 years and both genders.
  2. Patients with hemoptysis due to infective pathology.
  3. Patients with hemoptysis due to malignant pathology.
Exclusion Criteria
  1. Patients on antiplatelet therapy or aspirin
  2. Hemoptysis after penetrating lung injury e.g. firearm injury
  3. Patients with history of asthma

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group receiving tranexamic acid via IV routeTranexamic Acid (TXA)Tranrxamic acid has been used conventionally for hemoptysis via IV route
The Group receiving tranexamic acid via nebulizationTranexamic Acid (TXA)Tranexamic acid when given through nebulization can be more effective than IV route in controlling hemoptysis
Primary Outcome Measures
NameTimeMethod
Time to control hemoptysis48 hours

In this study the time taken by tranexamic acid to acehive comolete control of hemoptysis will be compared when given through IV and nebulization.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Services Hospital Lahore

🇵🇰

Lahore, Punjab Province, Pakistan

Services Hospital Lahore
🇵🇰Lahore, Punjab Province, Pakistan
Shoaib Nabi Buzdar Professor, MBBS, FCPS ( Thoracic Surgery)
Contact
+92 3009403511
One111@hotmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.